Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.

Sang S., Datoo MS., Otieno E., Muiruri C., Bellamy D., Gathuri E., Ngoto O., Musembi J., Provstgaard-Morys S., Stockdale L., Aboagye J., Woods D., Lawrie A., Roberts R., Keter K., Kimani D., Ndungu F., Kapulu M., Njau I., Orindi B., Ewer KJ., Hill AVS., Bejon P., Hamaluba M.

DOI

10.12688/wellcomeopenres.19795.1

Type

Preprint

Publication Date

01/01/2023

Keywords

Adults, CSP, Kenya, Matrix-M™, R21, age de-escalation, children, dose escalation, falciparum, immunogenicity, infants, safety

Permalink More information Close